Skip to main content
Unicycive loss widens to $7 million in Q3
Image for illustrative purposes only. Not a real photo.

Unicycive loss widens to $7 million in Q3

By

Key points

  • Unicycive Therapeutics (NASDAQ:UNCY) reported a third-quarter 2026 net loss of $6.997 million, compared with $6.011 million a year earlier.
  • Cash, cash equivalents and marketable securities totalled approximately $59 million at September 30, 2026, with funding expected to last beyond 2027.
  • The FDA accepted the resubmitted application for oxylanthanum carbonate (OLC), setting March 25, 2027, as its target decision date, subject to continued regulatory review.

Unicycive Therapeutics (NASDAQ:UNCY) reported a third-quarter 2026 net loss of $6.997 million, compared with $6.011 million a year earlier, while advancing its FDA review process for oxylanthanum carbonate.

The loss per share narrowed to $0.25 from $0.33, although total operating expenses increased to $8.841 million from $7.342 million in the prior-year quarter.

Research and development expenses declined to $2.246 million from $2.964 million, while general and administrative expenses increased to $6.595 million from $4.378 million, partly reflecting commercial launch preparations.

The company held approximately $59 million in cash, cash equivalents and marketable securities at September 30, and expects funding to support operations beyond 2027, including preparations for a potential OLC launch.

The FDA accepted OLC's resubmitted application in October and assigned a March 25, 2027, target action date after a June Complete Response Letter identified manufacturing-vendor deficiencies, while Unicycive plans commercial-leadership hires in the first quarter of 2027 and potential reimbursement remains subject to FDA approval and CMS eligibility confirmation.


Frequently asked questions